When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OBSV - ObsEva completes enrollment in late-stage study of linzagolix for heavy menstrual bleeding
ObsEva SA
ObsEva SA (NASDAQ:OBSV) has completed patient recruitment in its Phase 3 clinical trial PRIMROSE 1 evaluating oral gonadotropin releasing hormone (GnRH) receptor antagonist linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF).